Tivic Reports Second Quarter 2025 Financial Results

Company advances its TLR5 agonist program and prepares to report VNS clinical data FREMONT, Calif. – Tivic Health® Systems, Inc. (NASDAQ: TIVC), a diversified immunotherapeutics company, today announced financial results for the second quarter and six...